First commercial launch expected in 2022

Shareholders and financial community meeting

September 1st, 2021

mdc-IRM / TV46000

US NDA filing by Teva in June 2021

FDA NDA acceptance in August 2021

Commercial launch by Teva expected in 2022 in the US

Teva may assess development in other territories

mdc-IRM / TV46000

Extended-release subcutaneous injection of risperidone for the treatment of schizophrenia

1- or 2-month duration

Pivotal Phase 3 study (RISE) met its primary efficacy endpoint of delaying time to relapse

The RISE study

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of mdc-IRM/TV46000

544 patients (13–65 years)

Completed in November 2020

Statistically significant positive results:

1-month (n=183) and 2-month (n=179) acting products demonstrated a reduction of 80.0% and 62.5% in the risk to relapse compared to placebo (n=181), respectively ($p<0.0001$)

Schizophrenia

ca. 1% of the world population

3.5 million people diagnosed in the U.S.

Chronic, progressive and severely debilitating mental disorder

Multiple relapses experienced by most of patients

Treatment nonadherence, high discontinuation rates

Significant direct and indirect healthcare costs from subsequent relapses and hospitalizations

Antipsychotic LAIs market

(net sales reported by companies)



Global market
$ 6.1 Billion
12% 3-Year CAGR

US market
$ 3.7 Billion
14% 3-Year CAGR

Antipsychotic LAIs US market

$3.7 Billion in 2020 with 14% 3-Y CAGR

160K+ US patients diagnosed with schizophrenia use LAIs in 2020

Products based on risperidone and its metabolite are among the most frequently used

Yearly treatment cost from $ 19K to $ 25K
(LAIs based on risperidone and its metabolite - gross price)

Collaboration with Teva

3 antipsychotics in development

All operational and development costs covered by Teva

Potential revenue for MedinCell

- Development and commercial milestones: up to $122m for each product ($366m total)
- Single digit royalties on net sales



Exclusive Polymer supply by CMB

Customized copolymers for each product based on MedinCell proprietary technology

CMB: 50/50 Joint-venture with Corbion
(Amsterdam: CRBN)

Exclusive supply agreement with Teva

First product based on MedinCell proprietary technology is expected to reach market in 2022 with a strong potential

De-risking of the technology benefits to all pipeline assets

Long-Acting Injectable Portfolio

As of September 1st, 2021



*New Drug Application

In partnership with Teva Pharmaceuticals

In partnership with AIC

With the support of the Bill and Melinda Gates Foundation

With the support of Unitaid

Internal programs

Animal Health product
(different clinical development process)

mdc-IRM: commercialization expected in 2022

mdc-TJK: clinical Phase 1 analysis expected in 2021 to inform future development (Pivotal Phase 3)

mdc-ANG: start of clinical activities expected in 2021



mdc-CWM

- IND clearance for Pivotal phase 3 expected in 2021
- Safety study expected to start in 2022



mdc-WWM: clinical activities expected to start in 2023

mdc-STM: clinical activities expected to start in 2023



mdc-GRT: clinical activities expected to start in 2022

mdc-TTG: oral Phase 2 to confirm the prophylactic efficacity of Ivermectin.

mdc-KPT: start of pivotal studies expected in 2022



Targeted Portfolio in H2 2022

- 1 approved product on market
- 6 investigational products in clinical
- Many candidates in formulation and preclinical



Comprehensive antipsychotic portfolio taking shape

Growing portfolio based on validated technology

Acceleration of partnering discussions